As Tecentriq Growth Slows, Roche’s Imminent TIGIT Readout Is Crucial

Aims To Challenge Keytruda Dominance

 
• By Andrew McConaghie
  
Roche_HQ
Roche's SKYSCRAPER 1 trial aims to improve on the overall survival benchmark set in NSCLC by Keytruda. • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip